Shots:

• The P-III ICARIA-MM study results involve assessing of Isatuximab (10mg/kg- qw) + pomalidomide and dexamethasone (pom-dex) vs pom-dex in 307 patients with r/r multiple myeloma across 24 countries
• The P-III ICARIA-MM study result: improvement in m-PFS (11.53mos. vs 6.47 mos.); ORR (60% vs 35%); VGPR rate (31.8% vs 8.5%); DOR (13.27mos. vs 11.07mos); median time to first response (35 days vs 58 days)- presented at ASCO 2019 in Chicago
• Isatuximab is a mAb targeting specific epitope on the CD38 receptor- designed to promote apoptosis & immunomodulatory activity- currently being evaluated in multiple P-III studies for multiple myeloma. EMA has accepted its MAA in Q2’19 and Sanofi has also filed FDA’s BLA for RRMM

Ref: Sanofi | Image: Etoile